Harry Paul Erba | Scholars@Duke

Harry Paul Erba
Instructor in the Department of Medicine

I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine. I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies. I am also the Chair of the SWOG Leukemia Committee. I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia. Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.

Current Research Interests

I am a clinical investigator. I develop new therapies for people with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes and myeloproliferative neoplasms, including chronic myeloid leukemia. I have been the principal investigator for phase I, II and III studies.

Office Hours

Office hours:
Monday, 8 a.m. to 12 p.m.
Tuesday, 8 a.m. to 5 p.m.
Wednesday, 8 a.m. to 12 p.m.
Friday, 1 p.m. to 5 p.m.

Current Appointments & Affiliations

Instructor in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2018
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2018

Contact Information

2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
DUMC Box 3961, Durham, NC 27710
harry.erba@duke.edu (919) 668-1000
CV 080118
Erba Bio 080118
NIH Biosketch 080118

Background
Education, Training, & Certifications
- Research Fellowship in Medicine, Medicine, Harvard Medical School 1991 - 1993
- Research/Clinical Fellowship in Medicine, Medicine, Brigham and Women's Hospital 1991 - 1992
- Clinical Fellow in Medicine, Medicine, Harvard Medical School 1988 - 1991
- Residency Physician, Medicine, Brigham and Women's Hospital 1988 - 1990
- M.D., Stanford University, School of Medicine 1988
- Ph.D., Stanford University 1988
Medical Licensure
- 2018-01322. North Carolina. 2018
- MD.31788. Alabama. 2012
Leadership & Clinical Positions at Duke
- Director, Leukemia Program, Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine
  Director, Phase I Development in Hematologic Malignancies
Academic Positions Outside Duke
- Chair, Leukemia Committee, SWOG. 2012 - 2022
Recognition
Awards & Honors
Expertise
Subject Headings
Global Scholarship
- Research
  - Alabama (State or Province)
  - Michigan (State or Province)
- Teaching
  - Alabama (State or Province)
  - Michigan (State or Province)
Research
Selected Grants
- ALX Oncology: I/II of ALX148 in combo with Aza in patients with higher risk MDS awarded by ALX Oncology 2020 - 2026
- ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naive Patients with Higher Risk Myelodysplastic Syndrome awarded by Forty Seven, Inc. 2020 - 2025
- Agios MDS and Organ Impairment study awarded by Agios Pharmaceuticals, Inc. 2020 - 2025
- A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia awarded by Amgen, Inc. 2020 - 2025
- Jazz 1b CPX-351 previously untreated AML awarded by Jazz Pharmaceuticals 2020 - 2025
- NCI National Clinical Trials Network (UG1) awarded by National Institutes of Health 2019 - 2025
- Ph1b in patients with Hem Malignancies awarded by Forty Seven, Inc. 2020 - 2025
- ImmunoGen_0802: Ph 1b/2 IMGN632 awarded by ImmunoGen, Inc. 2020 - 2025
- Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias awarded by PTC Therapeutics, Inc 2020 - 2025
- A PHASE 1 STUDY OF DS-3032B IN COMBINATION WITH QUIZARTINIB IN SUBJECTS WITH FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA THAT ARE RELAPSED/REFRACTORY, OR NEWLY DIAGNOSED AND UNFIT FOR INTENSIVE CHEMOTHERAPY awarded by Daiichi Sankyo Inc 2019 - 2024
- A Phase I Study of DS-3201B in Subjects With Acute Myelogenous Leukemia (AML) Or Acute Lymphocytic Leukemia (ALL) awarded by Daiichi Sankyo Inc 2018 - 2024
- A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia awarded by GlycoMimetics, Inc 2018 - 2023
- A phase 1, Multi-center, open-label study of IMGN632 administered intravenously in patients with relapsed/refractory CD123-positive acute myeloid leukemia and other CD123-positive hematologic mali awarded by ImmunoGen, Inc. 2018 - 2023
- Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia awarded by AbbVie Inc. 2018 - 2023
- Novartis Phase II MBG453 in combination with Venetoclax and Azacitidine in AML awarded by Novartis Pharmaceuticals Corporation 2020 - 2023
- A Phase I/Ib, Multicenter, Open-Label, Dose-Escalation Study of FT-2102 as a Single agent and in Combination with Azacitidine in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation awarded by FORMA Therapeutics, Inc. 2018 - 2023
- A phase Ib, multi-arm, open-label, study of HDM201 in combination with MBG453 or venetoclax in adult subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) awarded by Novartis Pharmaceuticals Corporation 2020 - 2022
- NCTN Network Group Operations Center awarded by Oregon Health & Science University 2019 - 2021
- A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD 123 X CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia awarded by MacroGenics, Inc. 2015 - 2021
- SWOG Network Group Operations Center of the NCTN awarded by Oregon Health & Science University 2018 - 2019
External Relationships
- AbbVie, Inc.
- Agios Pharmaceuticals
- Astellas Pharma Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- Covance
- Daiichi Sankyo Co., Ltd
- Dava Oncology
- Glycomimetics
- Janssen Pharmaceuticals (Johnson & Johnson)
- Jazz Pharmaceuticals
- Novartis
- Pfizer Inc.
- incyte
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Arber, Daniel A., and Harry P. Erba. “Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).” Am J Clin Pathol 154, no. 6 (November 4, 2020): 731–41. https://doi.org/10.1093/ajcp/aqaa107.
    Full Text Link to Item
  - Uy, Geoffrey L., Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani, John E. Godwin, et al. “Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.” Blood, September 14, 2020. https://doi.org/10.1182/blood.2020007732.
    Full Text Link to Item
  - Shah, Gaurav, Fady M. Mikhail, Kimo Bachiasvili, Pankit Vachhani, Harry P. Erba, and Nikolaos Papadantonakis. “Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.” Hematol Oncol Stem Cell Ther 13, no. 3 (September 2020): 143–46. https://doi.org/10.1016/j.hemonc.2019.08.006.
    Full Text Link to Item
  - Sekeres, Mikkael A., Gordon Guyatt, Gregory Abel, Shabbir Alibhai, Jessica K. Altman, Rena Buckstein, Hannah Choe, et al. “American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.” Blood Adv 4, no. 15 (August 11, 2020): 3528–49. https://doi.org/10.1182/bloodadvances.2020001920.
    Full Text Link to Item
  - Othus, Megan, Aasthaa Bansal, Harry Erba, and Scott Ramsey. “Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up.” Value Health 23, no. 8 (August 2020): 1034–39. https://doi.org/10.1016/j.jval.2020.02.015.
    Full Text Link to Item
  - Zeidan, Amer M., Prajwal C. Boddu, Mrinal M. Patnaik, Jan Philipp Bewersdorf, Maximilian Stahl, Raajit K. Rampal, Rory Shallis, et al. “Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.” Lancet Haematol 7, no. 8 (August 2020): e601–12. https://doi.org/10.1016/S2352-3026(20)30205-2.
    Full Text Link to Item
  - Pagel, John M., Megan Othus, Guillermo Garcia-Manero, Min Fang, Jerald P. Radich, David A. Rizzieri, Guido Marcucci, et al. “Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.” Jco Oncology Practice 16, no. 6 (June 2020): e464–75. https://doi.org/10.1200/jop.19.00133.
    Full Text
  - Sung, Anthony D., Shekeab Jauhari, Sharareh Siamakpour-Reihani, Arati V. Rao, Janet Staats, Cliburn Chan, Everett Meyer, et al. “Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.” American Journal of Hematology 95, no. 6 (June 2020): 662–71. https://doi.org/10.1002/ajh.25781.
    Full Text
  - Lancet, Jeffrey E., Anna B. Moseley, Steven E. Coutre, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, and Frederick R. Appelbaum. “A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).” Blood Advances 4, no. 8 (April 2020): 1683–89. https://doi.org/10.1182/bloodadvances.2019001278.
    Full Text
  - Merz, Lauren E., Anthony J. Perissinotti, Bernard L. Marini, Patrick W. Burke, Ashley Crouch, Harry P. Erba, and Dale Bixby. “Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.” Clin Lymphoma Myeloma Leuk 20, no. 1 (January 2020): 24–30. https://doi.org/10.1016/j.clml.2019.09.615.
    Full Text Link to Item
  - Pogosova-Agadjanyan, Era L., Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen, Harry P. Erba, et al. “AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report.” Biomark Res 8 (2020): 29. https://doi.org/10.1186/s40364-020-00208-1.
    Full Text Link to Item
  - Roboz, Gail J., Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, et al. “Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.” Blood, December 16, 2019. https://doi.org/10.1182/blood.2019002140.
    Full Text
  - Shanafelt, Tait D., Victoria Wang, Neil E. Kay, Curtis A. Hanson, Susan M. O’Brien, Jacqueline C. Barrientos, Diane F. Jelinek, et al. “Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial.” Blood 134, no. Supplement_1 (November 13, 2019): 33. https://doi.org/10.1182/blood-2019-126824.
    Full Text Link to Item
  - Ustun, Celalettin, Jennifer Le-Rademacher, Hai-Lin Wang, Megan Othus, Zhuoxin Sun, Brittny Major, Mei-Jie Zhang, et al. “Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.” Leukemia 33, no. 11 (November 2019): 2599–2609. https://doi.org/10.1038/s41375-019-0477-x.
    Full Text Link to Item
  - Perl, Alexander E., Giovanni Martinelli, Jorge E. Cortes, Andreas Neubauer, Ellin Berman, Stefania Paolini, Pau Montesinos, et al. “Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.” The New England Journal of Medicine 381, no. 18 (October 2019): 1728–40. https://doi.org/10.1056/nejmoa1902688.
    Full Text
  - Shanafelt, Tait D., Xin V. Wang, Neil E. Kay, Curtis A. Hanson, Susan O’Brien, Jacqueline Barrientos, Diane F. Jelinek, et al. “Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.” N Engl J Med 381, no. 5 (August 1, 2019): 432–43. https://doi.org/10.1056/NEJMoa1817073.
    Full Text Link to Item
  - Erba, Harry P., Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson, and Eunice S. Wang. “Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.” Blood Adv 3, no. 13 (July 9, 2019): 1939–49. https://doi.org/10.1182/bloodadvances.2019030916.
    Full Text Link to Item
  - LeBlanc, Thomas W., and Harry P. Erba. “Shifting paradigms in the treatment of older adults with AML.” Semin Hematol 56, no. 2 (April 2019): 110–17. https://doi.org/10.1053/j.seminhematol.2019.02.002.
    Full Text Link to Item
  - Stock, Wendy, Selina M. Luger, Anjali S. Advani, Jun Yin, Richard C. Harvey, Charles G. Mullighan, Cheryl L. Willman, et al. “A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.” Blood 133, no. 14 (April 2019): 1548–59. https://doi.org/10.1182/blood-2018-10-881961.
    Full Text
  - Medeiros, Bruno C., Megan Othus, Martin S. Tallman, Zhuoxin Sun, Hugo F. Fernandez, Jacob M. Rowe, Hillard M. Lazarus, et al. “The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).” Leuk Res 78 (March 2019): 29–33. https://doi.org/10.1016/j.leukres.2019.01.007.
    Full Text Link to Item
  - Othus, Megan, Elihu H. Estey, Guillermo Garcia-Manero, Brent L. Wood, Derek L. Stirewalt, John E. Godwin, James K. Weick, et al. “Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.” Leukemia 33, no. 2 (February 2019): 554–58. https://doi.org/10.1038/s41375-018-0274-y.
    Full Text Link to Item
  - Othus, Megan, Mikkael A. Sekeres, Sucha Nand, Guillermo Garcia-Manero, Frederick R. Appelbaum, Harry P. Erba, and Eli Estey. “Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.” Leukemia 33, no. 2 (February 2019): 371–78. https://doi.org/10.1038/s41375-018-0275-x.
    Full Text Open Access Copy Link to Item
  - Nazha, Aziz, Mikkael A. Sekeres, Rafael Bejar, Michael J. Rauh, Megan Othus, Rami S. Komrokji, John Barnard, et al. “Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence.” Jco Precis Oncol 3 (2019). https://doi.org/10.1200/po.19.00119.
    Full Text Open Access Copy Link to Item
  - Woyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, et al. “Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.” N Engl J Med 379, no. 26 (December 27, 2018): 2517–28. https://doi.org/10.1056/NEJMoa1812836.
    Full Text Link to Item
  - Halpern, Anna B., Megan Othus, Emily M. Huebner, Bart L. Scott, Pamela S. Becker, Mary-Elizabeth M. Percival, Paul C. Hendrie, et al. “Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.” Leukemia 32, no. 11 (November 2018): 2352–62. https://doi.org/10.1038/s41375-018-0135-8.
    Full Text Open Access Copy
  - Jamy, Omer, Sejong Bae, Luciano J. Costa, Harry P. Erba, and Nikolaos Papadantonakis. “Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.” Leuk Res 74 (November 2018): 64–67. https://doi.org/10.1016/j.leukres.2018.09.014.
    Full Text Link to Item
  - Stahl, Maximilian, Alexander Pine, Jeanne E. Hendrickson, Mark R. Litzow, Selina M. Luger, Richard M. Stone, Harry P. Erba, et al. “Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.” Leuk Lymphoma 59, no. 11 (November 2018): 2723–26. https://doi.org/10.1080/10428194.2018.1452219.
    Full Text Link to Item
  - Fathi, Amir T., Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi, Stefan Faderl, Roland B. Walter, et al. “A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.” Blood 132, no. 11 (September 13, 2018): 1125–33. https://doi.org/10.1182/blood-2018-03-841171.
    Full Text Link to Item
  - DiNardo, Courtney D., Eytan M. Stein, Stéphane de Botton, Gail J. Roboz, Jessica K. Altman, Alice S. Mims, Ronan Swords, et al. “Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.” N Engl J Med 378, no. 25 (June 21, 2018): 2386–98. https://doi.org/10.1056/NEJMoa1716984.
    Full Text Link to Item
  - Statler, Abby, Megan Othus, Harry P. Erba, Thomas R. Chauncey, Jerald P. Radich, Steven Coutre, Anjali Advani, et al. “Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.” Blood 131, no. 25 (June 21, 2018): 2782–88. https://doi.org/10.1182/blood-2018-01-826693.
    Full Text Link to Item
  - Advani, Anjali S., Hongli Li, Laura C. Michaelis, Bruno C. Medeiros, Michaela Liedtke, Alan F. List, Kristen O’Dwyer, Megan Othus, Harry P. Erba, and Frederick R. Appelbaum. “Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).” Leuk Res 67 (April 2018): 17–20. https://doi.org/10.1016/j.leukres.2018.01.021.
    Full Text Link to Item
  - Swords, Ronan T., Steven Coutre, Michael B. Maris, Joshua F. Zeidner, James M. Foran, Jose Cruz, Harry P. Erba, et al. “Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.” Blood 131, no. 13 (March 2018): 1415–24. https://doi.org/10.1182/blood-2017-09-805895.
    Full Text
  - Pogosova-Agadjanyan, Era L., Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen, Harry P. Erba, et al. “Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.” Biopreserv Biobank 16, no. 1 (February 2018): 42–52. https://doi.org/10.1089/bio.2017.0079.
    Full Text Link to Item
  - Walter, Roland B., Laura C. Michaelis, Megan Othus, Geoffrey L. Uy, Jerald P. Radich, Richard F. Little, Sandi Hita, et al. “Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.” Am J Hematol 93, no. 2 (February 2018): E49–52. https://doi.org/10.1002/ajh.24980.
    Full Text Link to Item
  - Stein, Eytan M., Roland B. Walter, Harry P. Erba, Amir T. Fathi, Anjali S. Advani, Jeffrey E. Lancet, Farhad Ravandi, et al. “A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.” Blood 131, no. 4 (January 2018): 387–96. https://doi.org/10.1182/blood-2017-06-789800.
    Full Text
  - Perl, Alexander E., Jessica K. Altman, Jorge Cortes, Catherine Smith, Mark Litzow, Maria R. Baer, David Claxton, et al. “Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.” The Lancet. Oncology 18, no. 8 (August 2017): 1061–75. https://doi.org/10.1016/s1470-2045(17)30416-3.
    Full Text Open Access Copy
  - Qu, Xiaoyu, Megan Othus, Jerry Davison, Yu Wu, Liying Yan, Soheil Meshinchi, Fabiana Ostronoff, et al. “Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.” Cancer 123, no. 13 (July 1, 2017): 2472–81. https://doi.org/10.1002/cncr.30626.
    Full Text Link to Item
  - Mantha, Simon, Debra A. Goldman, Sean M. Devlin, Ju-Whei Lee, Diana Zannino, Marnie Collins, Dan Douer, et al. “Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.” Blood 129, no. 13 (March 2017): 1763–67. https://doi.org/10.1182/blood-2016-10-747170.
    Full Text
  - Swords, R. T., J. Watts, H. P. Erba, J. K. Altman, M. Maris, F. Anwer, Z. Hua, et al. “Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.” Blood Cancer J 7, no. 2 (February 3, 2017): e520. https://doi.org/10.1038/bcj.2017.1.
    Full Text Open Access Copy Link to Item
  - Moinpour, Carol M., Joseph M. Unger, Patricia A. Ganz, Alice B. Kornblith, Ellen R. Gaynor, Mindy Ann Bowers, Gretchen S. Gatti, et al. “Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208.” J Cancer Surviv 11, no. 1 (February 2017): 32–40. https://doi.org/10.1007/s11764-016-0559-y.
    Full Text Link to Item
  - Pine, Alexander B., Eun-Ju Lee, Mikkael Sekeres, David P. Steensma, Daniel Zelterman, Thomas Prebet, Amy DeZern, et al. “Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.” Transfusion 57, no. 2 (February 2017): 289–95. https://doi.org/10.1111/trf.13934.
    Full Text
  - Minagawa, Kentaro, Muhammad O. Jamil, Mustafa Al-Obaidi, Larisa Pereboeva, Donna Salzman, Harry P. Erba, Lawrence S. Lamb, Ravi Bhatia, Shin Mineishi, and Antonio Di Stasi. “Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.” Plos One 12, no. 2 (2017): e0172640. https://doi.org/10.1371/journal.pone.0172640.
    Full Text Open Access Copy Link to Item
  - Ravandi, Farhad, Megan Othus, Susan M. O’Brien, Stephen J. Forman, Chul S. Ha, Jeffrey Y. C. Wong, Martin S. Tallman, et al. “US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.” Blood Advances 1, no. 3 (December 2016): 250–59. https://doi.org/10.1182/bloodadvances.2016001495.
    Full Text
  - Othus, M., B. L. Wood, D. L. Stirewalt, E. H. Estey, S. H. Petersdorf, F. R. Appelbaum, H. P. Erba, and R. B. Walter. “Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.” Leukemia 30, no. 10 (October 2016): 2080–83. https://doi.org/10.1038/leu.2016.120.
    Full Text Link to Item
  - Steensma, David P., Medrdad Abedi, Rafael Bejar, Christopher R. Cogle, Kathryn Foucar, Guillermo Garcia-Manero, Tracy I. George, et al. “Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.” Bmc Cancer 16 (August 19, 2016): 652. https://doi.org/10.1186/s12885-016-2710-6.
    Full Text Link to Item
  - Othus, M., S. Mukherjee, M. A. Sekeres, J. Godwin, S. Petersdorf, F. R. Appelbaum, H. Erba, and E. Estey. “Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.” Leukemia 30, no. 8 (August 2016): 1779–80. https://doi.org/10.1038/leu.2016.48.
    Full Text Link to Item
  - Othus, Megan, Wim van Putten, Bob Lowenberg, Stephen H. Petersdorf, Sucha Nand, Harry Erba, Frederick Appelbaum, et al. “Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI.” Haematologica 101, no. 7 (July 2016): e284–86. https://doi.org/10.3324/haematol.2015.138552.
    Full Text Link to Item
  - Achille, Nicholas J., Megan Othus, Kathleen Phelan, Shubin Zhang, Kathrine Cooper, John E. Godwin, Frederick R. Appelbaum, et al. “Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.” Leuk Res 42 (March 2016): 68–74. https://doi.org/10.1016/j.leukres.2016.01.004.
    Full Text Link to Item
  - Prebet, Thomas, Zhuoxin Sun, Rhett P. Ketterling, Amer Zeidan, Peter Greenberg, James Herman, Mark Juckett, et al. “Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.” Br J Haematol 172, no. 3 (February 2016): 384–91. https://doi.org/10.1111/bjh.13832.
    Full Text Link to Item
  - Minagawa, Kentaro, Muhammad O. Jamil, Mustafa Al-Obaidi, Larisa Pereboeva, Donna Salzman, Harry P. Erba, Lawrence S. Lamb, Ravi Bhatia, Shin Mineishi, and Antonio Di Stasi. “In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.” Plos One 11, no. 12 (January 2016): e0166891. https://doi.org/10.1371/journal.pone.0166891.
    Full Text
  - Walter, Roland B., Megan Othus, Bob Löwenberg, Gert J. Ossenkoppele, Stephen H. Petersdorf, Thomas Pabst, Marie-Christiane Vekemans, Frederick R. Appelbaum, Harry P. Erba, and Elihu H. Estey. “Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.” Haematologica 100, no. 10 (October 2015): e409–11. https://doi.org/10.3324/haematol.2015.130013.
    Full Text Link to Item
  - Ravandi, Farhad, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael D. Craig, Norbert Vey, Stephen A. Strickland, et al. “Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.” The Lancet. Oncology 16, no. 9 (September 2015): 1025–36. https://doi.org/10.1016/s1470-2045(15)00201-6.
    Full Text
  - Tefferi, Ayalew, Hagop Kantarjian, S Vincent Rajkumar, Lawrence H. Baker, Jan L. Abkowitz, John W. Adamson, Ranjana Hira Advani, et al. “In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.” Mayo Clinic Proceedings 90, no. 8 (August 2015): 996–1000. https://doi.org/10.1016/j.mayocp.2015.06.001.
    Full Text
  - DiPersio, John F., Harry P. Erba, Richard A. Larson, Selina M. Luger, Martin S. Tallman, Jeffrey M. Brill, Gregoire Vuagniaux, Elisabeth Rouits, J Mel Sorensen, and Claudio Zanna. “Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.” Clin Lymphoma Myeloma Leuk 15, no. 7 (July 2015): 443–49. https://doi.org/10.1016/j.clml.2015.02.020.
    Full Text Link to Item
  - Swords, Ronan T., Harry P. Erba, Daniel J. DeAngelo, Dale L. Bixby, Jessica K. Altman, Michael Maris, Zhaowei Hua, et al. “Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.” Br J Haematol 169, no. 4 (May 2015): 534–43. https://doi.org/10.1111/bjh.13323.
    Full Text Link to Item
  - Stone, Richard M., Emanuele Mazzola, Donna Neuberg, Steven L. Allen, Arnaud Pigneux, Robert K. Stuart, Meir Wetzler, et al. “Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.” J Clin Oncol 33, no. 11 (April 10, 2015): 1252–57. https://doi.org/10.1200/JCO.2014.57.0952.
    Full Text Link to Item
  - Erba, Harry P. “Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.” Am J Hematol 90, no. 3 (March 2015): 242–49. https://doi.org/10.1002/ajh.23902.
    Full Text Link to Item
  - Medeiros, Bruno C., Megan Othus, Min Fang, Frederick R. Appelbaum, and Harry P. Erba. “Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.” Haematologica 100, no. 3 (March 2015): 331–35. https://doi.org/10.3324/haematol.2014.117267.
    Full Text Link to Item
  - Michaelis, Laura C., and Harry P. Erba. “Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014.” Curr Opin Hematol 22, no. 2 (March 2015): 108–15. https://doi.org/10.1097/MOH.0000000000000120.
    Full Text Link to Item
  - Othus, Megan, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn Slovak, Thomas Nevill, Joseph Brandwein, et al. “Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.” Biol Blood Marrow Transplant 21, no. 3 (March 2015): 559–64. https://doi.org/10.1016/j.bbmt.2014.10.025.
    Full Text Link to Item
  - Erba, Harry P. “Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.” Leuk Res 39, no. 2 (February 2015): 183–91. https://doi.org/10.1016/j.leukres.2014.11.027.
    Full Text Link to Item
  - Lindsley, R Coleman, Brenton G. Mar, Emanuele Mazzola, Peter V. Grauman, Sarah Shareef, Steven L. Allen, Arnaud Pigneux, et al. “Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.” Blood 125, no. 9 (February 2015): 1367–76. https://doi.org/10.1182/blood-2014-11-610543.
    Full Text
  - Zeidan, Amer M., Ju-Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R. Smith, et al. “Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.” Br J Haematol 167, no. 1 (October 2014): 62–68. https://doi.org/10.1111/bjh.13008.
    Full Text Link to Item
  - Zeidan, Amer M., Ju-Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R. Smith, et al. “Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.” Br J Haematol 166, no. 3 (August 2014): 352–59. https://doi.org/10.1111/bjh.12884.
    Full Text Link to Item
  - Prebet, Thomas, Zhuoxin Sun, Maria E. Figueroa, Rhett Ketterling, Ari Melnick, Peter L. Greenberg, James Herman, et al. “Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.” J Clin Oncol 32, no. 12 (April 20, 2014): 1242–48. https://doi.org/10.1200/JCO.2013.50.3102.
    Full Text Link to Item
  - Erba, Harry P., Megan Othus, Roland B. Walter, Mark H. Kirschbaum, Martin S. Tallman, Richard A. Larson, Marilyn L. Slovak, Kenneth J. Kopecky, Holly M. Gundacker, and Frederick R. Appelbaum. “Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.” Leuk Res 38, no. 3 (March 2014): 329–33. https://doi.org/10.1016/j.leukres.2013.12.001.
    Full Text Link to Item
  - Othus, M., H. Kantarjian, S. Petersdorf, F. Ravandi, J. Godwin, J. Cortes, S. Pierce, et al. “Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.” Leukemia 28, no. 2 (February 2014): 289–92. https://doi.org/10.1038/leu.2013.176.
    Full Text Link to Item
  - Jain, Nitin, Emily Curran, Neil M. Iyengar, Ernesto Diaz-Flores, Rangesh Kunnavakkam, Leslie Popplewell, Mark H. Kirschbaum, et al. “Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.” Clin Cancer Res 20, no. 2 (January 15, 2014): 490–98. https://doi.org/10.1158/1078-0432.CCR-13-1311.
    Full Text Link to Item
  - Schimmer, Aaron D., Azra Raza, Thomas H. Carter, David Claxton, Harry Erba, Daniel J. DeAngelo, Martin S. Tallman, Carolyn Goard, and Gautam Borthakur. “A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.” Plos One 9, no. 10 (January 2014): e108694. https://doi.org/10.1371/journal.pone.0108694.
    Full Text Open Access Copy
  - Nand, Sucha, Megan Othus, John E. Godwin, Cheryl L. Willman, Thomas H. Norwood, Dianna S. Howard, Steven E. Coutre, Harry P. Erba, and Frederick R. Appelbaum. “A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.” Blood 122, no. 20 (November 14, 2013): 3432–39. https://doi.org/10.1182/blood-2013-06-506592.
    Full Text Link to Item
  - Ravandi, Farhad, Harry P. Erba, and Daniel A. Pollyea. “Expert insights into the contemporary management of older adults with acute myeloid leukemia.” Cancer Control 20, no. 4 Suppl (October 2013): 5–16. https://doi.org/10.1177/107327481302004s02.
    Full Text Link to Item
  - Erba, Harry P., Hamid Sayar, Mark Juckett, Michael Lahn, Valerie Andre, Sophie Callies, Shelly Schmidt, et al. “Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).” Invest New Drugs 31, no. 4 (August 2013): 1023–34. https://doi.org/10.1007/s10637-013-9935-x.
    Full Text Link to Item
  - Petersdorf, Stephen H., Kenneth J. Kopecky, Marilyn Slovak, Cheryl Willman, Thomas Nevill, Joseph Brandwein, Richard A. Larson, et al. “A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.” Blood 121, no. 24 (June 13, 2013): 4854–60. https://doi.org/10.1182/blood-2013-01-466706.
    Full Text Link to Item
  - Roth, Bruce J., Lada Krilov, Sylvia Adams, Carol A. Aghajanian, Peter Bach, Fadi Braiteh, Marcia S. Brose, et al. “Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology.” J Clin Oncol 31, no. 1 (January 1, 2013): 131–61. https://doi.org/10.1200/JCO.2012.47.1938.
    Full Text Link to Item
  - Borate, Uma, Devin Absher, Harry P. Erba, and Boris Pasche. “Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.” Expert Rev Anticancer Ther 12, no. 10 (October 2012): 1289–97. https://doi.org/10.1586/era.12.116.
    Full Text Link to Item
  - Claxton, David, Harry P. Erba, Stefan Faderl, Martha Arellano, Roger M. Lyons, Tibor Kovacsovics, Janice Gabrilove, et al. “Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.” Leuk Lymphoma 53, no. 3 (March 2012): 435–40. https://doi.org/10.3109/10428194.2011.616960.
    Full Text Link to Item
  - Li, Meng, Roxane Collins, Yuchen Jiao, Peter Ouillette, Dale Bixby, Harry Erba, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, and Sami N. Malek. “Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia.” Blood 118, no. 22 (November 24, 2011): 5914–17. https://doi.org/10.1182/blood-2011-05-356204.
    Full Text Link to Item
  - Erba, Harry P., Dat C. Pham, Robert Zaiden, Ho Vu, and Shawn Tai. “Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.” Clin Adv Hematol Oncol 9, no. 10 (October 2011): 734–45.
    Link to Item
  - Magenau, John, Hiromi Tobai, Attaphol Pawarode, Thomas Braun, Edward Peres, Pavan Reddy, Carrie Kitko, et al. “Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.” Blood 118, no. 15 (October 2011): 4258–64. https://doi.org/10.1182/blood-2011-06-358010.
    Full Text
  - Saiya-Cork, Kamlai, Roxane Collins, Brian Parkin, Peter Ouillette, Erlene Kuizon, Lisa Kujawski, Harry Erba, et al. “A pathobiological role of the insulin receptor in chronic lymphocytic leukemia.” Clin Cancer Res 17, no. 9 (May 1, 2011): 2679–92. https://doi.org/10.1158/1078-0432.CCR-10-2058.
    Full Text Link to Item
  - Levis, Mark, Farhad Ravandi, Eunice S. Wang, Maria R. Baer, Alexander Perl, Steven Coutre, Harry Erba, et al. “Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.” Blood 117, no. 12 (March 24, 2011): 3294–3301. https://doi.org/10.1182/blood-2010-08-301796.
    Full Text Link to Item
  - Sekeres, Mikkael A., Jaroslaw P. Maciejewski, Harry P. Erba, Manuel Afable, Ricki Englehaupt, Ronald Sobecks, Anjali Advani, Sherry Seel, Josephine Chan, and Matt E. Kalaycio. “A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.” Cancer 117, no. 6 (March 15, 2011): 1253–61. https://doi.org/10.1002/cncr.25686.
    Full Text Link to Item
  - Wang, Meng, Bruno C. Medeiros, Harry P. Erba, Daniel J. DeAngelo, Francis J. Giles, and Ronan T. Swords. “Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer.” Expert Opin Ther Targets 15, no. 3 (March 2011): 253–64. https://doi.org/10.1517/14728222.2011.550877.
    Full Text Link to Item
  - Erba, Harry P. “Has there been progress in the treatment of older patients with acute myeloid leukemia?” Best Pract Res Clin Haematol 23, no. 4 (December 2010): 495–501. https://doi.org/10.1016/j.beha.2010.09.012.
    Full Text Link to Item
  - Parkin, Brian, Harry Erba, Peter Ouillette, Diane Roulston, Anjali Purkayastha, Judith Karp, Moshe Talpaz, et al. “Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.” Blood 116, no. 23 (December 2010): 4958–67. https://doi.org/10.1182/blood-2010-01-266999.
    Full Text
  - Parkin, Brian, Peter Ouillette, Yin Wang, Yan Liu, Whitney Wright, Diane Roulston, Anjali Purkayastha, et al. “NF1 inactivation in adult acute myelogenous leukemia.” Clin Cancer Res 16, no. 16 (August 15, 2010): 4135–47. https://doi.org/10.1158/1078-0432.CCR-09-2639.
    Full Text Link to Item
  - Long, Jianting, Brian Parkin, Peter Ouillette, Dale Bixby, Kerby Shedden, Harry Erba, Shaomeng Wang, and Sami N. Malek. “Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.” Blood 116, no. 1 (July 8, 2010): 71–80. https://doi.org/10.1182/blood-2010-01-261628.
    Full Text Link to Item
  - Kantarjian, Hagop M., Harry P. Erba, David Claxton, Martha Arellano, Roger M. Lyons, Tibor Kovascovics, Janice Gabrilove, et al. “Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.” J Clin Oncol 28, no. 4 (February 1, 2010): 549–55. https://doi.org/10.1200/JCO.2009.23.3130.
    Full Text Link to Item
  - Chauncey, Thomas R., Holly Gundacker, Mazyar Shadman, Alan F. List, Shaker R. Dakhil, Harry P. Erba, Marilyn L. Slovak, et al. “Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.” Br J Haematol 148, no. 1 (January 2010): 48–58. https://doi.org/10.1111/j.1365-2141.2009.07919.x.
    Full Text Link to Item
  - O’Brien, Susan, Ellin Berman, Hossein Borghaei, Daniel J. Deangelo, Marcel P. Devetten, Steven Devine, Harry P. Erba, et al. “NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.” J Natl Compr Canc Netw 7, no. 9 (October 2009): 984–1023. https://doi.org/10.6004/jnccn.2009.0065.
    Full Text Link to Item
  - Radich, Jerald P., Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, et al. “NCCN task force report: molecular markers in leukemias and lymphomas.” J Natl Compr Canc Netw 7 Suppl 4 (July 2009): S1-34. https://doi.org/10.6004/jnccn.2009.0077.
    Full Text Link to Item
  - Crawford, Jeffrey, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, et al. “Myeloid growth factors.” J Natl Compr Canc Netw 7, no. 1 (January 2009): 64–83. https://doi.org/10.6004/jnccn.2009.0006.
    Full Text Link to Item
  - Allen, Steven L., Harry P. Erba, David A. Rizzieri, Margaret O’Donnell, Bayard Powell, Ante S. Lundberg, John M. Bennett, and Robert L. Capizzi. “Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML.” Blood 112, no. 11 (November 16, 2008): 1019–20.
    Link to Item
  - O’Donnell, Margaret R., Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, Harry P. Erba, James Foran, Jeffrey Lancet, et al. “Acute myeloid leukemia.” J Natl Compr Canc Netw 6, no. 10 (November 2008): 962–93. https://doi.org/10.6004/jnccn.2008.0074.
    Full Text Link to Item
  - Greenberg, Peter L., Eyal Attar, Minoo Battiwalla, John M. Bennett, Clara D. Bloomfield, Carlos M. DeCastro, H Joachim Deeg, et al. “Myelodysplastic syndromes.” Journal of the National Comprehensive Cancer Network : Jnccn 6, no. 9 (October 2008): 902–26. https://doi.org/10.6004/jnccn.2008.0072.
    Full Text
  - Kujawski, Lisa, Peter Ouillette, Harry Erba, Chris Saddler, Andrzej Jakubowiak, Mark Kaminski, Kerby Shedden, and Sami N. Malek. “Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia.” Blood 112, no. 5 (September 1, 2008): 1993–2003. https://doi.org/10.1182/blood-2007-07-099432.
    Full Text Link to Item
  - Rizzieri, D. A., H. P. Erba, M. O’Donnell, B. L. Powell, A. S. Lundberg, J. M. Bennett, and R. L. Capizzi. “Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 7027–7027. https://doi.org/10.1200/jco.2008.26.15_suppl.7027.
    Full Text
  - Ouillette, Peter, Harry Erba, Lisa Kujawski, Mark Kaminski, Kerby Shedden, and Sami N. Malek. “Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.” Cancer Res 68, no. 4 (February 15, 2008): 1012–21. https://doi.org/10.1158/0008-5472.CAN-07-3105.
    Full Text Link to Item
  - Saddler, Chris, Peter Ouillette, Lisa Kujawski, Sanjeev Shangary, Moshe Talpaz, Mark Kaminski, Harry Erba, Kerby Shedden, Shaomeng Wang, and Sami N. Malek. “Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.” Blood 111, no. 3 (February 1, 2008): 1584–93. https://doi.org/10.1182/blood-2007-09-112698.
    Full Text Link to Item
  - Greineder, Colin F., Patrick W. Nelson, Amanda L. Dressel, Harry P. Erba, and John G. Younger. “In vitro and in silico analysis of annexin V binding to lymphocytes as a biomarker in emergency department sepsis studies.” Acad Emerg Med 14, no. 9 (September 2007): 763–71. https://doi.org/10.1197/j.aem.2007.01.017.
    Full Text Link to Item
  - Shehab, Nadine, Daryl D. DePestel, Emily R. Mackler, Curtis D. Collins, Kathleen Welch, and Harry P. Erba. “Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.” Pharmacotherapy 27, no. 7 (July 2007): 970–79. https://doi.org/10.1592/phco.27.7.970.
    Full Text Link to Item
  - O’Brien, Susan, Ellin Berman, Kapil Bhalla, Edward A. Copelan, Marcel P. Devetten, Peter D. Emanuel, Harry P. Erba, et al. “Chronic myelogenous leukemia.” J Natl Compr Canc Netw 5, no. 5 (May 2007): 474–96. https://doi.org/10.6004/jnccn.2007.0043.
    Full Text Link to Item
  - Crawford, Jeffrey, Betsy Althaus, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, et al. “Myeloid growth factors. Clinical practice guidelines in oncology.” J Natl Compr Canc Netw 5, no. 2 (February 2007): 188–202. https://doi.org/10.6004/jnccn.2007.0019.
    Full Text Link to Item
  - Erba, Harry P. “Prognostic factors in elderly patients with AML and the implications for treatment.” Hematology Am Soc Hematol Educ Program, 2007, 420–28. https://doi.org/10.1182/asheducation-2007.1.420.
    Full Text Link to Item
  - Greenberg, Peter L., Maria R. Baer, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H Joachim Deeg, Marcel P. Devetten, et al. “Myelodysplastic syndromes clinical practice guidelines in oncology.” J Natl Compr Canc Netw 4, no. 1 (January 2006): 58–77.
    Link to Item
  - O’Donnell, Margaret R., Frederick R. Appelbaum, Maria R. Baer, John C. Byrd, Steven E. Coutre, Lloyd E. Damon, Harry P. Erba, et al. “Acute myeloid leukemia clinical practice guidelines in oncology.” J Natl Compr Canc Netw 4, no. 1 (January 2006): 16–36. https://doi.org/10.6004/jnccn.2006.0004.
    Full Text Link to Item
  - O’Brien, Susan, Ellin Berman, Kapil Bhalla, Edward A. Copelan, Marcel P. Devetten, Peter D. Emanuel, Harry P. Erba, et al. “Chronic myelogenous leukemia.” J Natl Compr Canc Netw 3, no. 6 (November 2005): 732–55. https://doi.org/10.6004/jnccn.2005.0044.
    Full Text Link to Item
  - Erba, Harry P. “Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.” Curr Hematol Rep 3, no. 1 (January 2004): 47–53.
    Link to Item
  - Ganz, Patricia A., Carol M. Moinpour, Donna K. Pauler, Alice B. Kornblith, Ellen R. Gaynor, Stanley P. Balcerzak, Gretchen S. Gatti, et al. “Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133.” J Clin Oncol 21, no. 18 (September 15, 2003): 3512–19. https://doi.org/10.1200/JCO.2003.01.044.
    Full Text Link to Item
  - Erba, Harry Paul. “Recent progress in the treatment of myelodysplastic syndrome in adult patients.” Curr Opin Oncol 15, no. 1 (January 2003): 1–9. https://doi.org/10.1097/00001622-200301000-00001.
    Full Text Link to Item
  - Larson, R. A., M. Boogaerts, E. Estey, C. Karanes, E. A. Stadtmauer, E. L. Sievers, P. Mineur, et al. “Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).” Leukemia 16, no. 9 (September 2002): 1627–36. https://doi.org/10.1038/sj.leu.2402677.
    Full Text Link to Item
  - Appelbaum, F. R., M. R. Baer, M. H. Carabasi, S. E. Coutre, H. P. Erba, E. Estey, M. J. Glenn, et al. “NCCN Practice Guidelines for Acute Myelogenous Leukemia.” Oncology (Williston Park) 14, no. 11A (November 2000): 53–61.
    Link to Item
  - Berman, E., R. A. Clift, E. A. Copelan, P. D. Emanuel, H. P. Erba, M. J. Glenn, P. L. Greenberg, et al. “NCCN Practice Guidelines for Chronic Myelogenous Leukemia.” Oncology (Williston Park) 14, no. 11A (November 2000): 229–40.
    Link to Item
  - O’Donnell, M. R., F. R. Appelbaum, M. R. Baer, M. H. Carabasi, S. E. Coutre, H. P. Erba, E. Estey, et al. “NCCN Practice Guidelines for acute myelogenous leukemia.” Oncology New York 14, no. 11A (November 1, 2000): 53–61.
    Link to Item
  - Talpaz, M., E. Berman, R. A. Clift, E. A. Copelan, P. D. Emanuel, H. P. Erba, M. J. Glenn, et al. “NCCN Practice Guidelines for chronic myelogenous leukemia.” Oncology New York 14, no. 11A (November 1, 2000): 229–40.
    Link to Item
  - Paciocco, G., E. Bossone, H. Erba, and M. Rubenfire. “Reversible pulmonary hypertension in POEMS syndrome--another etiology of triggered pulmonary vasculopathy?” Can J Cardiol 16, no. 8 (August 2000): 1007–12.
    Link to Item
  - Taylor, A., H. P. Erba, G. E. Muscat, and L. Kedes. “Nucleotide sequence and expression of the human skeletal alpha-actin gene: evolution of functional regulatory domains.” Genomics 3, no. 4 (November 1988): 323–36. https://doi.org/10.1016/0888-7543(88)90123-1.
    Full Text Link to Item
  - Erba, H. P., R. Eddy, T. Shows, L. Kedes, and P. Gunning. “Structure, chromosome location, and expression of the human gamma-actin gene: differential evolution, location, and expression of the cytoskeletal beta- and gamma-actin genes.” Mol Cell Biol 8, no. 4 (April 1988): 1775–89. https://doi.org/10.1128/mcb.8.4.1775.
    Full Text Link to Item
  - Ng, S. Y., H. Erba, G. Latter, L. Kedes, and J. Leavitt. “Modulation of microfilament protein composition by transfected cytoskeletal actin genes.” Mol Cell Biol 8, no. 4 (April 1988): 1790–94. https://doi.org/10.1128/mcb.8.4.1790.
    Full Text Link to Item
  - Cross, G. S., C. Wilson, H. P. Erba, and H. R. Woodland. “Cytoskeletal actin gene families of Xenopus borealis and Xenopus laevis.” J Mol Evol 27, no. 1 (1988): 17–28. https://doi.org/10.1007/BF02099726.
    Full Text Link to Item
  - Stephenson, E. C., H. P. Erba, and J. G. Gall. “Histone gene clusters of the newt notophthalmus are separated by long tracts of satellite DNA.” Cell 24, no. 3 (June 1981): 639–47. https://doi.org/10.1016/0092-8674(81)90090-8.
    Full Text Link to Item
  - Gall, J. G., E. C. Stephenson, H. P. Erba, M. O. Diaz, and G. Barsacchi-Pilone. “Histone genes are located at the sphere loci of newt lampbrush chromosomes.” Chromosoma 84, no. 2 (1981): 159–71. https://doi.org/10.1007/BF00399128.
    Full Text Link to Item
  - Varley, J. M., H. C. Macgregor, and H. P. Erba. “Satellite DNA is transcribed on lampbrush chromosomes.” Nature 283, no. 5748 (February 14, 1980): 686–88. https://doi.org/10.1038/283686a0.
    Full Text Link to Item
  - Varley, J. M., H. C. Macgregor, I. Nardi, C. Andrews, and H. P. Erba. “Cytological evidence of transcription of highly repeated DNA sequences during the lampbrush stage in Triturus cristatus carnifex.” Chromosoma 80, no. 3 (1980): 289–307. https://doi.org/10.1007/BF00292686.
    Full Text Link to Item
- Book Sections
  - Borate, U., and H. P. Erba. “Cytogenetics and Prognostic Models in Myelodysplastic Syndromes.” In Cancer Consult: Expertise for Clinical Practice, 106–12, 2014. https://doi.org/10.1002/9781118589199.ch15.
    Full Text
- Conference Papers
  - DiNardo, Courtney D., Gail J. Roboz, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, et al. “Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study.” In Clinical Lymphoma Myeloma and Leukemia, 19:S220–S220. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.07.094.
    Full Text
  - DeAngelo, Daniel J., Harry Paul Erba, Brian Andrew Jonas, Michael O’Dwyer, Paula Marlton, Gerwin A. Huls, Jane Liesveld, et al. “A phase Ill trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
    Link to Item
  - Roboz, Gail J., Courtney Denton Dinardo, Eytan M. Stein, Stephane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, et al. “Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
    Link to Item
  - Advani, Anjali S., Anna Moseley, Kristen Marie O’Dwyer, Brent Wood, Min Fang, Matthew J. Wieduwilt, Ibrahim Aldoss, et al. “Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia.” In Blood, 132:33–33. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-111992.
    Full Text
  - Cortes, Jorge E., Daniel J. DeAngelo, Harry P. Erba, Elie Traer, Nikolaos Papadantonakis, Cecilia Arana-Yi, William Blum, et al. “Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia.” In Blood, 132:26–26. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-112891.
    Full Text
  - Daver, Naval G., Harry P. Erba, Nikolaos Papadantonakis, Daniel J. DeAngelo, Eunice S. Wang, Marina Y. Konopleva, Callum M. Sloss, Kerry Culm-Merdek, Patrick A. Zweidler-McKay, and Hagop M. Kantarjian. “A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies.” In Blood, 132:27–27. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-112955.
    Full Text
  - Jamy, Omer, Charles Bodine, Rehan Sarmad, Awal Chadha, Pankit Vachhani, Luciano J. Costa, Ayman Saad, Nikolaos Papadantonakis, Harry P. Erba, and Antonio Di Stasi. “Outcomes of Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results Treated with and without Re-Induction Chemotherapy.” In Blood, 132:2688–2688. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-114090.
    Full Text
  - Merz, Lauren E., Anthony J. Perissinotti, Bernard Lawrence Marini, Ashley Crouch, Kristen Pettit, Patrick W. Burke, Harry P. Erba, and Dale L. Bixby. “Lenalidomide Plus Hypomethylating Agent for Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities -AML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, Mecom.” In Blood, 132:4042–4042. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-110854.
    Full Text
  - Mukherjee, Sudipto, Mehrdad Abedi, Harry P. Erba, Daniel A. Pollyea, Gail J. Roboz, Michael A. Thompson, Chrystal U. Louis, et al. “Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect® MDS/AML Disease Registry.” In Blood, 132:4736–4736. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-112935.
    Full Text
  - Othus, Megan, Elihu H. Estey, Guillermo Garcia-Manero, Brent Wood, Derek Stirewalt, John Godwin, James K. Weick, et al. “2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials.” In Blood, 132:3978–3978. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-117525.
    Full Text
  - Othus, Megan, Guillermo Garcia-Manero, Frederick R. Appelbaum, Harry P. Erba, and Roland B. Walter. “Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203.” In Blood, 132:1403–1403. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-117565.
    Full Text
  - Roboz, Gail J., Courtney D. DiNardo, Eytan M. Stein, Stephane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, et al. “Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study.” In Blood, 132:561–561. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-110595.
    Full Text
  - Shah, Gaurav, Fady M. Mikhail, Harry P. Erba, and Nikolaos Papadantonakis. “Omission of Maintenance in Patients with High-Risk Acute Promyelocytic Leukemia (APL) in the Era of ATRA/Arsenic Consolidation.” In Blood, 132:5192–5192. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-114872.
    Full Text
  - Shanafelt, Tait D., Victoria Wang, Neil E. Kay, Curtis A. Hanson, Susan M. O’Brien, Jacqueline C. Barrientos, Harry P. Erba, Richard M. Stone, Mark R. Litzow, and Martin S. Tallman. “A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912).” In Blood, Vol. 132. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-120779.
    Full Text
  - Stanko, Laura M., Luciano J. Costa, Denise Peker, Harry P. Erba, and Nikolaos Papadantonakis. “The Impact of Cumulative Dose of Cytarabine Consolidation on Outcomes in Older Patients with Acute Myeloid Leukemia.” In Blood, 132:2687–2687. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-117769.
    Full Text
  - Ustun, Celalettin, Jennifer Le-Rademacher, Hai-Lin Wang, Megan Othus, Zhuoxin Sun, Brittny Major, Mei-Jie Zhang, et al. “Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study.” In Blood, 132:2170–2170. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-118383.
    Full Text
  - Woyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, et al. “Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202.” In Blood, 132:6–6. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-116653.
    Full Text
  - DiNardo, Courtney D., Eytan M. Stein, Stéphane de Botton, Gail J. Roboz, Jessica K. Altman, Alice S. Mims, Ronan Swords, et al. “Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study.” In Clinical Lymphoma Myeloma and Leukemia, 18:S204–5. Elsevier BV, 2018. https://doi.org/10.1016/j.clml.2018.07.057.
    Full Text
  - George, Tracy, Kathryn Foucar, Daniel Pollyea, Harry Erba, Michael Thompson, Gail Roboz, John Pagel, et al. “Antecedent Conformity of Diagnostic and Molecular Testing Patterns in Clinical Practice for Newly Diagnosed Acute Myeloid Leukemia With American Society of Hematology and College of American Pathologists Guidelines.” In American Journal of Clinical Pathology, 149:S82–83. OXFORD UNIV PRESS INC, 2018.
    Link to Item
  - Cortes, Jorge E., Elie Traer, Eunice S. Wang, Harry P. Erba, William Blum, Cecilia Arana-Yi, Callum M. Sloss, et al. “IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
    Link to Item
  - DiNardo, Courtney D., Stephane De Botton, Eytan M. Stein, Gail J. Roboz, Alice S. Mims, Daniel A. Pollyea, Ronan T. Swords, et al. “Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
    Link to Item
  - Foran, James M., Yanming Zhang, Michael Heckman, Selina Luger, Cassondra Hulshizer, Emily Vargas, Mark R. Litzow, et al. “Prospective Study of Acute Myeloid Leukemia (AML) Clinical Epidemiology and Cytogenetic Risk Group in Older Adults in the ECOG-ACRIN E2906 Clinical Trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) Study.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
    Link to Item
  - Jamy, Omer, Sejong Bae, Luciano J. Costa, Harry P. Erba, and Nikolaos Papadantonakis. “Favorable Outcomes with Fludarabine, High Dose Cytarabine and Granulocyte Colony Stimulating Factor (FLAG) As Re-Induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
    Link to Item
  - Othus, Megan, Guillermo Garcia-Manero, John Godwin, James K. Weick, Jeanne E. Anderson, Derek Stirewalt, Frederick R. Appelbaum, Harry P. Erba, and Elihu H. Estey. “Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
    Link to Item
  - Ritchie, Ellen K., Rosalind Catchatourian, Rebecca B. Klisovic, Javier Pinilla-Ibarz, Michael W. Deininger, Harry P. Erba, Jerald P. Radich, et al. “Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
    Link to Item
  - Stahl, Maximilian, Alexander Pine, Jeanne E. Hendrickson, Mark R. Litzow, Selina Luger, Richard M. Stone, Harry P. Erba, et al. “Beliefs and Patterns of Practice in the Management of Hyperleukocytosis and Leukostasis Among Health Care Providers for Patients with Acute Leukemia: A Large North American Web-Based Survey.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
    Link to Item
  - Schlenk, R., H. Dombret, S. Amadori, P. Montesinos, M. Levis, M. A. Sekeres, J. Cortes, et al. “QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML).” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
    Link to Item
  - Sekeres, Mikkael A., Megan Othus, Alan F. List, Olatoyosi Odenike, Richard M. Stone, Steven D. Gore, Mark R. Litzow, et al. “Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.” In Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 35:2745–53, 2017. https://doi.org/10.1200/jco.2015.66.2510.
    Full Text
  - Cortes, J., D. DeAngelo, E. Wang, C. Arana-Yi, P. Zweidler-McKay, M. Munteanu, C. Andreu-Vieyra, H. Erba, W. Blum, and E. Traer. “INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML.” In Haematologica, 102:217–18. FERRATA STORTI FOUNDATION, 2017.
    Link to Item
  - Lancet, J. E., D. Rizzieri, G. J. Schiller, R. K. Stuart, J. E. Kolitz, S. R. Solomon, L. F. Newell, et al. “OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY.” In Haematologica, 102:214–15. FERRATA STORTI FOUNDATION, 2017.
    Link to Item
  - Levy, M. Y., A. S. Stein, S. Vasu, M. B. Maris, A. S. Advani, A. T. Fathi, S. Faderl, et al. “A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA.” In Haematologica, 102:324–324. FERRATA STORTI FOUNDATION, 2017.
    Link to Item
  - Medeiros, B. C., D. Hogge, L. F. Newell, D. L. Bixby, S. R. Solomon, S. A. Strickland, T. L. Lin, et al. “OVERALL SURVIVAL AND TRANSPLANTATION IN PATIENTS WITH FLT3 MUTATIONS: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA.” In Haematologica, 102:53–54. FERRATA STORTI FOUNDATION, 2017.
    Link to Item
  - Pollyea, D., T. George, K. Foucar, H. Erba, M. Thompson, G. Roboz, D. Landau, et al. “MOLECULAR GENETIC TESTING PATTERNS FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) ENROLLED IN THE CONNECT (R) MDS/AML DISEASE REGISTRY.” In Haematologica, 102:379–379. FERRATA STORTI FOUNDATION, 2017.
    Link to Item
  - Ravandi, M., A. Stein, H. Erba, J. Lancet, E. Stein, S. Faderl, R. Walter, et al. “VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS: A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIAF.” In Haematologica, 102:48–49. FERRATA STORTI FOUNDATION, 2017.
    Link to Item
  - Erba, Harry Paul, Pamela S. Becker, Paul J. Shami, Michael Richard Grunwald, Donna L. Flesher, Yilong Zhang, Erik Rasmussen, Haby A. Henary, and Eunice S. Wang. “Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).” In Journal of Clinical Oncology, 35:7027–7027. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.7027.
    Full Text
  - Lancet, Jeffrey E., David Rizzieri, Gary J. Schiller, Robert K. Stuart, Jonathan E. Kolitz, Scott R. Solomon, Laura F. Newell, et al. “Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.” In Journal of Clinical Oncology, 35:7035–7035. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.7035.
    Full Text
  - Medeiros, Bruno C., Donna Hogge, Laura F. Newell, Dale L. Bixby, Scott R. Solomon, Stephen Anthony Strickland, Tara L. Lin, et al. “Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).” In Journal of Clinical Oncology, 35:e18507–e18507. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e18507.
    Full Text
  - Pollyea, Daniel Aaron, Tracy George, Kathryn M. Foucar, Harry Paul Erba, Michael A. Thompson, Mehrdad Abedi, Gail J. Roboz, et al. “Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry.” In Journal of Clinical Oncology, 35:7022–7022. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.7022.
    Full Text
  - George, T. I., H. P. Erba, D. A. Pollyea, M. Abedi, G. J. Roboz, M. A. Thompson, A. Fliss, et al. “CURRENT DIAGNOSIS PATTERNS FOR ACUTE MYELOID LEUKEMIA: CONCORDANCE BETWEEN CLINICAL PRACTICE (CONNECT (R) DISEASE REGISTRY) AND WHO 2008 RECOMMENDATIONS.” In Leukemia Research, 55:S106–S106. PERGAMON-ELSEVIER SCIENCE LTD, 2017.
    Link to Item
  - Siniard, Rance, Jennifer J. Burczyk-Brown, Kelly Godby, Harry Erba, and Marisa B. Marques. “Downward Platelet Utilization Trends in Acute Leukemia.” In American Journal of Clinical Pathology, 147:S155–56. Oxford University Press (OUP), 2017. https://doi.org/10.1093/ajcp/aqw191.008.
    Full Text
  - Walter, R., H. Erba, and F. Ravandi. “A Phase 1b Study of Vadastuximab Talirine (33A) in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML).” In Annals of Hematology, 96:S69–S69. SPRINGER, 2017.
    Link to Item
  - Advani, Anjali S., Anna Moseley, Michaela Liedtke, Margaret O’Donnell, Megan Othus, Martha P. Mims, Kristen O’Dwyer, and Harry P. Erba. “A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia (SWOG 1312).” In Blood, 128:1634–1634. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.1634.1634.
    Full Text
  - Bixby, Dale L., Anthony S. Stein, Amir T. Fathi, Tibor J. Kovacsovics, Moshe Y. Levy, Harry P. Erba, Jeffrey E. Lancet, et al. “Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML).” In Blood, 128:590–590. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.590.590.
    Full Text
  - Erba, Harry P., Moshe Y. Levy, Sumithira Vasu, Anthony S. Stein, Amir T. Fathi, Michael B. Maris, Anjali Advani, et al. “A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML).” In Blood, 128:211–211. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.211.211.
    Full Text
  - Fathi, Amir T., Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi, Stefan Faderl, Roland B. Walter, et al. “Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML).” In Blood, 128:591–591. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.591.591.
    Full Text
  - Garcia-Manero, Guillermo, Megan Othus, John M. Pagel, Jerald P. Radich, Min Fang, David A. Rizzieri, Guido Marcucci, et al. “SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML).” In Blood, 128:901–901. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.901.901.
    Full Text
  - George, Tracy I., Harry P. Erba, David P. Steensma, Daniel A. Pollyea, Mehrdad Abedi, Rafael Bejar, Christopher R. Cogle, et al. “Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT® Myelodysplastic Syndromes (MDS) and AML Disease Registry.” In Blood, 128:3548–3548. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.3548.3548.
    Full Text
  - Halpern, Anna B., Megan Othus, Emily M. Huebner, Kaysey F. Orlowski, Bart L. Scott, Heather A. Smith, Pamela S. Becker, et al. “A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).” In Blood, 128:1068–1068. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.1068.1068.
    Full Text
  - Othus, Megan, Mikkael A. Sekeres, Sucha Nand, Guillermo Garcia-Manero, Frederick R. Appelbaum, Harry P. Erba, and Elihu H. Estey. “Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival.” In Blood, 128:1613–1613. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.1613.1613.
    Full Text
  - Pagel, John M., Megan Othus, Guillermo Garcia-Manero, Min Fang, Jerald P. Radich, David A. Rizzieri, Guido Marcucci, et al. “Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat.” In Blood, 128:1166–1166. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.1166.1166.
    Full Text
  - Perl, Alexander E., Jessica K. Altman, Jorge E. Cortes, Catherine C. Smith, Mark Litzow, Maria R. Baer, David F. Claxton, et al. “Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).” In Blood, 128:1069–1069. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.1069.1069.
    Full Text
  - Pogosova-Agadjanyan, Era L., Anna Moseley, Brent L. Wood, Frederick R. Appelbaum, Thomas Chauncey, I-Ming L. Chen, Harry P. Erba, et al. “Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report.” In Blood, 128:2890–2890. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.2890.2890.
    Full Text
  - Ravandi, Farhad, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael Craig, Norbert Vey, Stephen A. Strickland, et al. “Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial.” In Blood, 128:903–903. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.903.903.
    Full Text
  - Ritchie, Ellen K., Rose Catchatourian, Rebecca B. Klisovic, Javier Pinilla-Ibarz, Michael W. Deininger, Harry P. Erba, Jerald P. Radich, et al. “ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib.” In Blood, 128:3090–3090. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.3090.3090.
    Full Text
  - Statler, Abby, Megan Othus, Harry P. Erba, Thomas R. Chauncey, Jerald P. Radich, Steven E. Coutre, Anjali S. Advani, et al. “Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies.” In Blood, 128:4002–4002. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.4002.4002.
    Full Text
  - Swords, Ronan T., Steven Coutre, Michael B. Maris, Joshua F. Zeidner, James M. Foran, Jose C. Cruz, Harry P. Erba, et al. “Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML).” In Blood, 128:98–98. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.98.98.
    Full Text
  - Yang, Jay, Farhad Ravandi, Anjali Advani, Sumithira Vasu, Roland B. Walter, Stefan Faderl, Anthony S. Stein, et al. “A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML).” In Blood, 128:340–340. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.340.340.
    Full Text
  - Fathi, A., H. Erba, J. Lancet, E. Stein, F. Ravandi, S. Faderl, R. Walter, et al. “SGN-CD33A IN COMBINATION WITH HYPOMETHYLATING AGENTS: A NOVEL, WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN OLDER PATIENTS WITH AML.” In Haematologica, 101:186–87. FERRATA STORTI FOUNDATION, 2016.
    Link to Item
  - Lancet, J., G. Uy, J. Cortes, L. Newell, T. Lin, E. Ritchie, S. Strickland, et al. “CPX-351 TREATMENT OF PREVIOUSLY UNTREATED OLDER AML PATIENTS WITH HIGH RISK AML MARKEDLY INCREASES THE RESPONSE RATE OVER 7+3 IN PATIENTS WITH FLT3 MUTATIONS.” In Haematologica, 101:186–186. FERRATA STORTI FOUNDATION, 2016.
    Link to Item
  - Erba, Harry Paul, Mark J. Levis, Mikkael A. Sekeres, Herve Dombret, Sergio Amadori, Oleg Zernovak, Derek Edward Mires, et al. “Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study.” In Journal of Clinical Oncology, 34:TPS7073–TPS7073. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps7073.
    Full Text
  - Hathaway, Amanda Redden, Deniz Peker, Bradford E. Jackson, Vamsi K. Kota, Bijal D. Shah, Ling Zhang, Anand P. Jillella, et al. “Early Allogeneic Stem Cell Transplantation Appears to Improve Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi-Institutional Review.” In Biology of Blood and Marrow Transplantation, 22:S202–S202. Elsevier BV, 2016. https://doi.org/10.1016/j.bbmt.2015.11.593.
    Full Text
  - Stein, Anthony S., Roland B. Walter, Anjali S. Advani, Phoenix A. Ho, and Harry P. Erba. “SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML).” In Biology of Blood and Marrow Transplantation, 22:S211–12. Elsevier BV, 2016. https://doi.org/10.1016/j.bbmt.2015.11.608.
    Full Text
  - Advani, Anjali S., Hongli Li, Laura C. Michaelis, Bruno C. Medeiros, Michaela Liedtke, Alan F. List, Kristen O’Dwyer, Megan Othus, Harry P. Erba, and Frederick R. Appelbaum. “Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Altman, Jessica K., Alexander E. Perl, Jorge E. Cortes, Mark J. Levis, Catherine C. Smith, Mark R. Litzow, Maria R. Baer, et al. “Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Borate, Uma, Amanda Redden Hathaway, Deniz Peker, Bradford E. Jackson, Vamsi K. Kota, Bijal D. Shah, Ling Zhang, et al. “Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi Institutional Review.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Borate, Uma, Vipin Lohiya, Garrett Sherwood, Bradford E. Jackson, and Harry P. Erba. “Impact of Available Therapies on Survival of Very Elderly Myelodysplastic Syndrome (MDS) Patients (Age above 75 yrs).” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Fathi, Amir T., Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Roland B. Walter, Daniel J. DeAngelo, Stefan Faderl, et al. “SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Lancet, Jeffrey E., Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Stephen A. Strickland, Gary J. Schiller, Norbert Vey, et al. “Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Ostronoff, Fabiana, Todd A. Alonzo, Megan Othus, Matthew A. Kutny, Robert B. Gerbing, Jerald P. Radich, Harry P. Erba, et al. “Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Othus, Megan, Brent L. Wood, Elihu H. Estey, Stephen Petersdorf, Frederick R. Appelbaum, Harry P. Erba, and Roland B. Walter. “Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Pine, Alexander B., Eun-Ju Lee, Mikkael A. Sekeres, David P. Steensma, Thomas Prebet, Amy E. DeZern, Rami S. Komrokji, et al. “North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Qu, Xiaoyu, Megan Othus, Jerry Davison, Liying Yan, Elihu H. Estey, Jerry Radich, Harry P. Erba, Frederick R. Appelbaum, and Min Fang. “Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Ravandi, Farhad, Megan Othus, Susan O’Brien, Stephen J. Forman, Chul S. Ha, Jeffrey Y. C. Wong, Martin S. Tallman, et al. “Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60.” In Blood, 126:796–796. American Society of Hematology, 2015. https://doi.org/10.1182/blood.v126.23.796.796.
    Full Text
  - Ritchie, Ellen K., Rosalind Catchatourian, Rebecca B. Klisovic, Michael W. Deininger, Harry P. Erba, Jerald P. Radich, Michael R. Savona, et al. “Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Sekeres, Mikkael A., Megan Othus, Alan F. List, Olatoyosi Odenike, Richard M. Stone, Steven D. Gore, Mark R. Litzow, et al. “Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Stein, Anthony S., Roland B. Walter, Harry P. Erba, Amir T. Fathi, Anjali S. Advani, Jeffrey E. Lancet, Farhad Ravandi, et al. “A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML).” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Carella, A. -. M., F. Ravandi, E. K. Ritchie, H. Sayar, J. E. Lancet, M. D. Craig, N. Vey, et al. “IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY.” In Haematologica, 100:1–1. FERRATA STORTI FOUNDATION, 2015.
    Link to Item
  - Krug, U., F. Ravandi, E. K. Ritchie, H. Sayar, J. E. Lancet, M. D. Craig, N. Vey, et al. “Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study.” In Oncology Research and Treatment, 38:121–121. KARGER, 2015.
    Link to Item
  - Perl, A., J. Altman, J. Cortes, M. Levis, C. Smith, M. Litzow, M. R. Baer, et al. “RESULTS OF A FIRST-IN-HUMAN, PHASE 1/2 TRIAL OF ASP2215, A SELECTIVE, POTENT ORAL INHIBITOR OF FLT3/AXL, IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.” In Haematologica, 100:317–18. FERRATA STORTI FOUNDATION, 2015.
    Link to Item
  - Ravandi, F., E. K. Ritchie, H. Sayar, J. E. Lancet, M. D. Craig, N. Vey, S. A. Strickland, et al. “ALLOGENEIC TRANSPLANT IN PATIENTS >= 60 YEARS OF AGE WITH FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA AFTER TREATMENT WITH VOSAROXIN OR PLACEBO PLUS CYTARABINE: RESULTS FROM VALOR.” In Haematologica, 100:42–42. FERRATA STORTI FOUNDATION, 2015.
    Link to Item
  - Ravandi, F., E. K. Ritchie, H. Sayar, J. E. Lancet, M. D. Craig, N. Vey, S. A. Strickland, et al. “IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY.” In Haematologica, 100:46–47. FERRATA STORTI FOUNDATION, 2015.
    Link to Item
  - Nand, Sucha, Nicholas Achille, Megan Othus, Kathleen Wren Phelan, Shubin Zhang, Kathrine A. Cooper, John E. Godwin, et al. “Association between early promoter methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT0065884).” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Schiller, Gary J., Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael D. Craig, Norbert Vey, Stephen Anthony Strickland, et al. “Allogeneic hematopoietic cell transplant (HCT) in patients (pts) >= 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Steensma, D., M. Abedi, R. Bejar, C. Cogle, K. Foucar, G. Garcia-Manero, T. George, et al. “249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY.” In Leukemia Research, 39:S124–S124. Elsevier BV, 2015. https://doi.org/10.1016/s0145-2126(15)30250-2.
    Full Text
  - Erba, Harry P., Samer K. Khaled, and Anthony S. Stein. “SGN-CD33A: Case Reports of Anti-Leukemic Activity and Bridge to Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML).” In Biology of Blood and Marrow Transplantation, 21:S185–86. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.282.
    Full Text
  - Innis-Shelton, Racquel, Donna Salzman, Antonio Di Stasi, Lawrence S. Lamb, Melissa Gazi, Lisa Williams, Luciano J. Costa, Harry Erba, Shin Mineishi, and Ayman Saad. “Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - Ravandi, Farhad, Ellen Ritchie, Hamid Sayar, Jeffrey Lancet, Michael D. Craig, Norbert Vey, Stephen A. Strickland, et al. “Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR).” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - Sekeres, Mikkael A., Megan Othus, Alan F. List, Olatoyosi Odenike, Richard M. Stone, Steven D. Gore, Mark R. Litzow, et al. “A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - Stein, Eytan M., Anthony Stein, Roland B. Walter, Amir T. Fathi, Jeffrey E. Lancet, Tibor J. Kovacsovics, Anjali S. Advani, et al. “Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML).” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - Stock, Wendy, Selina M. Luger, Anjali S. Advani, Susan Geyer, Richard C. Harvey, Charles G. Mullighan, Cheryl L. Willman, et al. “Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403.” In Blood, 124:796–796. American Society of Hematology, 2014. https://doi.org/10.1182/blood.v124.21.796.796.
    Full Text
  - Swords, Ronan T., Michael R. Savona, Michael B. Maris, Harry P. Erba, Jesus G. Berdeja, James M. Foran, Zhaowei Hua, et al. “Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - Walter, Roland B., Megan Othus, Bob Loewenberg, Gert J. Ossenkoppele, Stephen H. Petersdorf, Thomas Pabst, Marie-Christianne Vekemans, Frederick R. Appelbaum, Harry P. Erba, and Elihu H. Estey. “Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - Swords, R. T., M. R. Savona, M. B. Maris, H. P. Erba, Z. Hua, H. Faessel, S. J. Blakemore, F. Sedarati, B. J. Dezube, and B. C. Medeiros. “FIRST-IN-CLASS NAE INHIBITOR MLN4924 IN COMBINATION WITH AZACITIDINE FOR ACUTE MYELOID LEUKEMIA (AML) PATIENTS CONSIDERED UNFIT FOR CONVENTIONAL CHEMOTHERAPY: RESULTS FROM THE C15009 TRIAL.” In Haematologica, 99:223–24. FERRATA STORTI FOUNDATION, 2014.
    Link to Item
  - DiPersio, John F., Harry Paul Erba, Richard A. Larson, Selina M. Luger, Kenneth Francis Mangan, Martin S. Tallman, Jeffrey Mark Brill, et al. “Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).” In Journal of Clinical Oncology, 32:7029–7029. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.7029.
    Full Text
  - Steensma, David P., Mehrdad Abedi, Eyal C. Attar, Rafael Bejar, Christopher R. Cogle, Guillermo Garcia-Manero, David L. Grinblatt, et al. “Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry.” In Journal of Clinical Oncology, 32:TPS7126–TPS7126. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps7126.
    Full Text
  - Advani, Anjali S., Ben Sanford, Selina Luger, Meenakshi Devidas, Eric C. Larsen, Michaela Liedtke, Peter M. Voorhees, et al. “Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance).” In Blood, 122:3903–6. AMER SOC HEMATOLOGY, 2013.
    Link to Item
  - DeAngelo, Daniel J., Harry P. Erba, Michael B. Maris, Ronan T. Swords, Faiz Anwer, Jessica K. Altman, Zhaowei Hua, et al. “MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study.” In Blood, 122:1443–1443. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.1443.1443.
    Full Text
  - Fang, Min, Shannon McDonough, Megan Othus, Lily T. Zhuo, Diane Roulston, Harry Paul Erba, and Frederick R. Appelbaum. “Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing – Retrospective Review Of The SWOG Experience.” In Blood, 122:1383–1383. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.1383.1383.
    Full Text
  - Prebet, Thomas, Zhuoxin Sun, Rhett Ketterling, Peter L. Greenberg, Amer M. Zeidan, Mark R. Litzow, Janice L. Gabrilove, et al. “Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study.” In Blood, 122:2777–2777. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.2777.2777.
    Full Text
  - Advani, Anjali S., Shannon McDonough, Edward Copelan, Cheryl L. Willman, Deborah A. Mulford, Alan F. List, Mikkael A. Sekeres, Megan Othus, Harry P. Erba, and Frederick R. Appelbaum. “SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Donnellan, William Bruce, Monalisa Ghosh Ghosh, Sunil Rangarajan, Bradley Jackson, Uma Borate, Harry P. Erba, and James M. Foran. “Use of flow cytometry during induction chemotherapy to determine outcomes in acute myeloid leukemia.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Zeidan, Amer, Zhuoxin Sun, Thomas Prebet, Peter Greenberg, Mark Juckett, Mitchell Reed Smith, Elisabeth Paietta, et al. “Application of the French prognostic score (FPS) to assess overall survival (OS) in a US-based cohort of patients (pts) treated with azacitidine (Aza).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Zeidan, A., S. Zhuoxin, T. Prebet, P. Greenberg, M. Juckett, M. Smith, E. Paietta, et al. “P-124 Application of the French Prognostic Score to assess overall survival in a US-based cohort of patients treated with azacitidine.” In Leukemia Research, 37:S79–80. Elsevier BV, 2013. https://doi.org/10.1016/s0145-2126(13)70172-3.
    Full Text
  - Stone, R. M., F. R. Appelbaum, Couban St, H. Erba, R. A. Larson, R. Little, and M. S. Tallman. “North American Cooperative Trials in AML.” In Annals of Hematology, 92:S56–58. SPRINGER, 2013.
    Link to Item
  - Nand, Sucha, Megan Othus, John E. Godwin, Cheryl L. Willman, Thomas Norwood, Harry Paul Erba, Dianna Howard, Steven E. Coutre, and Frederick R. Appelbaum. “A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients.” In Blood, 120:3584–3584. American Society of Hematology, 2012. https://doi.org/10.1182/blood.v120.21.3584.3584.
    Full Text
  - Othus, Megan, Hagop M. Kantarjian, Stephen Petersdorf, Farhad Ravandi, Jorge E. Cortes, Sherry A. Pierce, Harry Paul Erba, Stefan Faderl, Frederick R. Appelbaum, and Elihu H. Estey. “Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA).” In Blood, 120:129–129. American Society of Hematology, 2012. https://doi.org/10.1182/blood.v120.21.129.129.
    Full Text
  - Jain, Nitin, Emily Curran, Neil M. Iyengar, Ernesto Diaz-Flores, Rangesh Kunnavakkam, Leslie Popplewell, Mark H. Kirschbaum, et al. “Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Nand, Sucha, Holly Gundacker, John E. Godwin, Cheryl L. Willman, Thomas Norwood, Harry Paul Erba, Dianna S. Howard, Steven E. Coutre, Megan Othus, and Frederick R. Appelbaum. “A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol-Report on the good-risk patients.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Ravandi, Farhad, Ellen K. Ritchie, Hamid Sayar, Stephen Anthony Strickland, Michael Craig, Dominik L. D. Selleslag, Johan Maertens, et al. “VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Pogosova-Agadjanyan, Era L., Kenneth J. Kopecky, Stephen Petersdorf, Harry Paul Erba, Richard M. Stone, Soheil Meshinchi, Thomas J. Nevill, et al. “Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG.” In Blood, 118:1080–1080. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Uy, Geoffrey L., David Avigan, Jorge E. Cortes, Pamela S. Becker, Robert W. Chen, Jane L. Liesveld, Becker Hewes, Don Johns, and Harry Paul Erba. “Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study.” In Blood, 118:39–40. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Mehta, C. R., G. Michelson, M. Salganik, J. Feaster, R. Allen, A. L. Cahill, J. A. Fox, et al. “Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia.” In Journal of Clinical Oncology, 29:TPS201–TPS201. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.tps201.
    Full Text
  - Shepard, D. D., H. E. Kohrt, T. L. Rosenblat, J. G. Jurcic, J. H. Park, A. Goldman, J. S. Dalal, et al. “Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed APL.” In Journal of Clinical Oncology, 29:6619–6619. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.6619.
    Full Text
  - Stone, R. M., S. L. Allen, A. Pigneux, R. K. Stuart, M. Wetzler, D. Rizzieri, H. P. Erba, et al. “A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE).” In Journal of Clinical Oncology, 29:6520–6520. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.6520.
    Full Text
  - Mineishi, Shin, John Magenau, Hiromi Tobai, Attaphol Pawarode, Edward M. Peres, Pavan Reddy, Carrie Kitko, et al. “Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML.” In Blood, 116:35–35. American Society of Hematology, 2010. https://doi.org/10.1182/blood.v116.21.35.35.
    Full Text
  - Mohan, Sanjay R., Jaroslaw P. Maciejewski, Bindu Tejura, Harry P. Erba, Richard M. Stone, and Mikkael A. Sekeres. “A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML.” In Blood, 116:883–84. AMER SOC HEMATOLOGY, 2010.
    Link to Item
  - Prebet, Thomas, Steven D. Gore, Zhuoxin Sun, Peter L. Greenberg, Mark Juckett, Lisa Malick, Mitchell R. Smith, et al. “Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905.” In Blood, 116:264–65. AMER SOC HEMATOLOGY, 2010.
    Link to Item
  - Prebet, Thomas, Zhuoxin Sun, Rhett Ketterling, Gary Hicks, C. L. Beach, Peter L. Greenberg, Elisabeth Paietta, et al. “A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study.” In Blood, 116:1636–1636. AMER SOC HEMATOLOGY, 2010.
    Link to Item
  - Swords, Ronan T., Harry P. Erba, Daniel J. DeAngelo, Peter G. Smith, Michael D. Pickard, Bruce J. Dezube, Francis J. Giles, and Bruno C. Medeiros. “The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study.” In Blood, 116:288–288. AMER SOC HEMATOLOGY, 2010.
    Link to Item
  - Sekeres, M., S. Allen, S. Mohan, A. Lundberg, and H. Erba. “TREATMENT-RELATED AML AND AML EVOLVING FROM MDS: SIMILAR OUTCOMES FOLLOWING TREATMENT WITH AMONAFIDE plus CYTARABINE.” In Haematologica the Hematology Journal, 95:273–273. FERRATA STORTI FOUNDATION, 2010.
    Link to Item
  - Sekeres, M. A., S. L. Allen, S. R. Mohan, A. S. Lundberg, and H. P. Erba. “Treatment-related AML and AML evolving from MDS: Similar outcomes following treatment with amonafide plus cytarabine.” In Journal of Clinical Oncology, 28:6582–6582. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.6582.
    Full Text
  - Magenau, J., A. Pawarode, T. Buck, D. Jones, K. Kato, A. Harris, D. Frame, et al. “Allogeneic haematopoietic cell transplantation with clofarabine/busulfan x 4 conditioning exhibits significant anti-leukaemic activity in non-remission AML.” In Bone Marrow Transplantation, 45:S79–80. NATURE PUBLISHING GROUP, 2010.
    Link to Item
  - Downie, Ben J., Harry P. Erba, Richard M. Stone, David A. Rizzieri, and James M. Foran. “Monosomal Karyotype Is Predictive of Poor Response to Therapy and Worse Overall Survival in Secondary Acute Myeloid Leukemia (sAML); Analysis of a Multi-Center Phase II Study of Amonafide and Cytarabine Induction Therapy.” In Blood, 114:2076–2076. American Society of Hematology, 2009. https://doi.org/10.1182/blood.v114.22.2076.2076.
    Full Text
  - Erba, Harry P., Margaret O’Donnell, Steven L. Allen, Maria R. Baer, Bayard L. Powell, Richard M. Stone, John M. Bennett, Ante S. Lundberg, Robert L. Capizzi, and David A. Rizzieri. “Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study.” In Blood, 114:1047–1047. American Society of Hematology, 2009. https://doi.org/10.1182/blood.v114.22.1047.1047.
    Full Text
  - Erba, Harry P., Stefan Faderl, David F. Claxton, M. Arellano, Roger M. Lyons, Tibor J. Kovacsovics, Janice Gabrilove, Stephen Eckert, Dirk Huebner, and Hagop M. Kantarjian. “Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.” In Blood, 114:822–23. AMER SOC HEMATOLOGY, 2009.
    Link to Item
  - Gabrilove, Janice, Stefan Faderl, Harry P. Erba, David F. Claxton, M. Arellano, Roger M. Lyons, Tibor J. Kovacsovics, Stephen Eckert, Dirk Huebner, and Hagop M. Kantarjian. “Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.” In Blood, 114:814–814. AMER SOC HEMATOLOGY, 2009.
    Link to Item
  - Levis, Mark, Farhad Ravandi, Eunice S. Wang, Maria R. Baer, Alexander Perl, Steven Coutre, Harry Erba, et al. “Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.” In Blood, 114:325–26. AMER SOC HEMATOLOGY, 2009.
    Link to Item
  - Malek, Sami, Brian Parkin, Peter Ouillette, Lisa Kujawski, Harry Paul Erba, Erica L. Campagnaro, Mark S. Kaminski, Kerby Shedden, and Kamlai Saiya-Cork. “A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia.” In Blood, 114:918–918. AMER SOC HEMATOLOGY, 2009.
    Link to Item
  - Malek, Sami, Peter Ouillette, Yin Wang, Yan Liu, Whitney Wright, Diane Roulston, Amanda L. Dressel, et al. “Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia.” In Blood, 114:73–74. AMER SOC HEMATOLOGY, 2009.
    Link to Item
  - Odenike, Olatoyosi, Emily Curran, Neil Iyengar, Leslie Popplewell, Mark Kirschbaum, Harry P. Erba, Margaret Green, et al. “Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).” In Blood, 114:2081–2081. American Society of Hematology, 2009. https://doi.org/10.1182/blood.v114.22.2081.2081.
    Full Text
  - Petersdorf, Stephen, Kenneth Kopecky, Robert K. Stuart, Richard A. Larson, Thomas J. Nevill, Leif Stenke, Marilyn L. Slovak, et al. “Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.” In Blood, 114:326–27. AMER SOC HEMATOLOGY, 2009.
    Link to Item
  - Erba, H. P. “Prognostic factors in elderly patients with myelodysplastic syndrome or acute myeloid leukemia and the implications for treatment.” In Clinical Advances in Hematology and Oncology, 7:3–6, 2009.
  - Lundberg, S., M. Chau, H. P. Erba, A. L. Dressel, G. Acton, R. L. Capizzi, and M. R. Baer. “AMONAFIDE (AS1413) IS UNAFFECTED BY MULTIDRUG RESISTANCE AND IS ASSOCIATED WITH A HIGH RESPONSE RATE IN PATIENTS WITH SECONDARY AML.” In Haematologica the Hematology Journal, 94:338–39. FERRATA STORTI FOUNDATION, 2009.
    Link to Item
  - Erba, H. P., H. M. Kantarjian, D. F. Claxton, M. Arellano, R. M. Lyons, T. J. Kovacsovics, J. Gabrilove, S. Eckert, and S. Faderl. “Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor (s).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Raza, A., N. Galili, G. Borthakur, T. H. Carter, D. F. Claxton, H. P. Erba, D. J. DeAngelo, M. S. Berger, and A. Schimmer. “A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Magenau, J., A. Pawarode, T. Buck, D. Jones, K. Kato, D. Frame, L. Kujawski, et al. “Conditioning with Clofarabine and Busulfan X 4 (CloBu4) For Non-Remission Hematologic Malignancies Including Aml Is Well Tolerated, Facilitates Secure Engraftment, And Exhibits Significant Anti-Tumor Activity.” In Biology of Blood and Marrow Transplantation, 15:104–104. Elsevier BV, 2009. https://doi.org/10.1016/j.bbmt.2008.12.321.
    Full Text
  - Erba, Harry Paul, Hagop Kantarjian, David F. Claxton, M. Arellano, Roger M. Lyons, Tibor J. Kovacsovics, Janice Gabrilove, Stephen Eckert, Rekha Abichandani, and Stefan Faderl. “Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy.” In Blood, 112:209–209. AMER SOC HEMATOLOGY, 2008.
    Link to Item
  - Long, Jianting, Peter Ouillette, Brian Parkin, Harry Erba, Shaomeng Wang, and Sami Malek. “Identification of p53 Aberration-Dependent as Well as Non-p53-Mediated Resistance to MDM2 Inhibitors in Acute Myelogenous Leukemia.” In Blood, 112:569–569. AMER SOC HEMATOLOGY, 2008.
    Link to Item
  - Malek, Sami, Peter Ouillette, Whitney Wright, Amanda Dressel, Judy Karp, Paula Bockenstedt, Ammar Al-Zoubi, et al. “Comprehensive Ultra High Resolution Analysis of Copy Number and Allele Status Including Novel Microdeletions Spanning NF1 in Acute Myelogenous Leukemia.” In Blood, 112:1066–1066. AMER SOC HEMATOLOGY, 2008.
    Link to Item
  - Mineishi, Shin, John Magenau, Attaphol Pawarode, Timothy Buck, Dawn Jones, Koji Kato, David Frame, et al. “Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.” In Blood, 112:749–749. AMER SOC HEMATOLOGY, 2008.
    Link to Item
  - Erba, H., H. Kantarjian, D. Claxton, M. Arellano, R. Lyons, T. Kovacsovics, J. Gabrilove, S. Eckert, R. Abichandani, and S. Faderl. “PHASE II STUDY OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) UNLIKELY TO BENEFIT FROM STANDARD INDUCTION CHEMOTHERAPY.” In Haematologica the Hematology Journal, 93:354–354. FERRATA STORTI FOUNDATION, 2008.
    Link to Item
  - Erba, H. P., H. M. Kantarjian, D. Claxton, M. Arellano, R. Lyons, T. Kovacsovics, J. Gabrilove, S. Eckert, R. Abichandani, and S. Faderl. “Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy.” In Journal of Clinical Oncology, 26:7025–7025. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.7025.
    Full Text
  - Lundberg, A. S., M. R. Baer, M. Chau, H. P. Erba, A. L. Dressel, A. M. Ajami, and R. L. Capizzi. “Blast cells from patients treated for secondary AML (sAML) show less P-glycoprotein (Pgp)-mediated efflux of amonafide compared to daunorubicin: Implications for therapy.” In Journal of Clinical Oncology, 26:13536–13536. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.13536.
    Full Text
  - Erba, H. P., K. J. Kopecky, M. H. Kirschbaum, M. S. Tallman, R. A. Larson, C. L. Willman, M. L. Slovak, H. M. Gundacker, and F. R. Appelbaum. “Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R115777, zarnestra) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): North American intergroup study S0432.” In Annals of Hematology, 87:S57–59. SPRINGER, 2008.
    Link to Item
  - Erba, Harry P., Kenneth J. Kopecky, Mark H. Kirschbaum, Martin S. Tallman, Richard A. Larson, Cheryl L. Willman, Marilyn L. Slovak, Holly M. Gundacker, and Frederick R. Appelbaum. “Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432).” In Blood, 110:440–440. American Society of Hematology, 2007. https://doi.org/10.1182/blood.v110.11.440.440.
    Full Text
  - Malek, Sami N., Peter Ouillette, Harry Erba, Chris Saddler, Andrzej Jakubowiak, Mark Kaminski, Kerby Shedden, and Lisa Kujawski. “Genomic complexity identifies patients with agressive chronic lymphocytic leukemia.” In Blood, 110:151A-151A. AMER SOC HEMATOLOGY, 2007.
    Link to Item
  - Malek, Sami N., Peter Ouillette, Lisa Kujawski, Sanjeev Shangary, Moshe Talpaz, Mark Kaminski, Harry Erba, Kerby Shedden, and Shaomeng Wang. “Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.” In Blood, 110:73A-73A. AMER SOC HEMATOLOGY, 2007.
    Link to Item
  - Malek, Sarm N., Harry Erba, Kaminski S. Mark, Shedden Kerby, and Ouillette Peter. “Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14 with differential expression of LATS2.” In Blood, 110:617A-617A. AMER SOC HEMATOLOGY, 2007.
    Link to Item
  - Erba, H. P., D. A. Rizzieri, M. R. O’Donnell, A. S. Lundberg, A. M. Ajami, A. D. Rampersad, and R. L. Capizzi. “Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Sekeres, M. A., M. E. Kalaycio, H. P. Erba, R. Sobecks, A. Advani, J. Chan, and J. P. Maciejewski. “P155 Arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in high-risk MDS or AML arising from MDS.” In Leukemia Research, 31:S125–S125. Elsevier BV, 2007. https://doi.org/10.1016/s0145-2126(07)70225-4.
    Full Text
  - Norwood, Thomas H., Holly M. Gundacker, Marilyn L. Slovak, Harry Paul Erba, and Frederick R. Appelbaum. “Changes in the pattern of cytogenetic aberrations with advancing age in acute myeloid (Non-APL) leukemia: A Southwest Oncology study (S9007).” In Blood, 108:242A-242A. AMER SOC HEMATOLOGY, 2006.
    Link to Item
  - Sekeres, Mikkael A., Jaroslaw P. Maciejewski, Harry Paul Erba, Ronald Sobecks, Anjali Advani, Julie Nichols, Josephine Chan, and Matt Kalaycio. “A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS.” In Blood, 108:2669–2669. American Society of Hematology, 2006. https://doi.org/10.1182/blood.v108.11.2669.2669.
    Full Text
  - Malek, Sami N., Lisa A. Kujawski, Harry P. Erba, Mark S. Kaminski, Andrzej Jakubowiak, Amanda Dressel, Chris M. Saddler, Kerby A. Shedden, and Peter D. Ouillette. “Genomic Profiling of Chronic Lymphocytic Leukemia Identifies Novel Genetic Subtypes.” In Blood, 108:2090–2090. American Society of Hematology, 2006. https://doi.org/10.1182/blood.v108.11.2090.2090.
    Full Text
  - Kujawski, Lisa A., Irene Ryan, Kent Griffith, and Harry P. Erba. “Combination of Daunorubicin and Cytarabine Chemotherapy with Gemtuzumab Ozogamicin as Initial Therapy for Elderly Patients with Previously Untreated Acute Myeloid Leukemia.” In Blood, 106:4636–4636. American Society of Hematology, 2005. https://doi.org/10.1182/blood.v106.11.4636.4636.
    Full Text
  - Levis, M., B. D. Smith, M. Beran, M. R. Baer, H. P. Erba, L. Cripe, S. Coutre, et al. “A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition.” In Blood, 106:121A-121A. AMER SOC HEMATOLOGY, 2005.
    Link to Item
  - Collins, C. D., D. D. DePestel, E. R. Stuntebeck, N. Shehab, H. P. Erba, and J. G. Stevenson. “PIN5 COST ANALYSIS OFA FEBRILE NEUTROPENIA ALGORITHM WITH RESPECT TO EMPIRICAL ANTIFUNGAL THERAPY IN ADULT HEMATOLOGY/ONCOLOGY PATIENTS.” In Value in Health, 8:306–306. Elsevier BV, 2005. https://doi.org/10.1016/s1098-3015(10)62788-x.
    Full Text
  - Kujawski, L. A., E. M. Gartner, I. Ryan, K. Griffith, and H. P. Erba. “Gemtuzumab ozogamicin (Mylotarg (R)) as primary induction therapy for elderly patients with acute myeloid leukemia: A phase II trial.” In Blood, 104:210B-210B. AMER SOC HEMATOLOGY, 2004.
    Link to Item
  - Erba, H. P., E. A. Stadtmauer, R. A. Larson, E. L. Sievers, E. H. Esrey, B. Lowenberg, M. L. Sherman, R. K. Herbertson, and F. R. Appelbaum. “Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg (R)) with or without hematopoietic stem cell transplantation.” In Blood, 102:871A-871A. AMER SOC HEMATOLOGY, 2003.
    Link to Item
  - Kilgore, S., H. Erba, R. Valdez, W. Finn, B. Schnitzer, and C. Ross. “Mylotarg (gemtuzumab ozogamicin; CMA-676) in AML: Predictive variables and response to treatment.” In Modern Pathology, 16:240A-240A. LIPPINCOTT WILLIAMS & WILKINS, 2003.
    Link to Item
  - Kilgore, S., H. Erba, R. Valdez, W. Finn, B. Schnitzer, and C. Ross. “Mylotarg(Gemtuzumab Ozogamicin;CMA-676) in AML: Predictive variables and response to treatment.” In Laboratory Investigation, 83:240A-240A. LIPPINCOTT WILLIAMS & WILKINS, 2003.
    Link to Item
  - Erba, H. P., E. A. Stadtmauer, R. A. Larson, E. L. Sievers, E. H. Estey, B. Lowenberg, L. H. Leopold, M. S. Berger, R. Herbertson, and F. R. Appelbaum. “Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin.” In Blood, 100:339A-339A. AMER SOC HEMATOLOGY, 2002.
    Link to Item
  - Raza, A., P. Fenaux, H. Erba, F. Mandelli, G. Schiller, R. Larson, C. Denzlinger, et al. “Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome.” In Blood, 100:795A-795A. AMER SOC HEMATOLOGY, 2002.
    Link to Item
  - Sievers, E. L., R. A. Larson, E. Estey, B. Lowenberg, H. P. Erba, M. Gramatzki, A. List, et al. “Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg (TM), CMA-676) followed by hematopoietic stem cell transplantation.” In Blood, 96:320A-320A. AMER SOC HEMATOLOGY, 2000.
    Link to Item
  - Sievers, E. L., R. A. Larson, E. Estey, E. A. Stadtmauer, H. P. Erba, D. C. C. Roy, L. Tarantolo, et al. “Efficacy and safety of CMA-676 in patients with AML in first relapse.” In Blood, 94:696A-696A. AMER SOC HEMATOLOGY, 1999.
    Link to Item
  - Alereidi, F., H. Terebelo, H. Erba, and C. Ross. “Transformation of chronic lymphocytic leukemia (CLL) to Hodgkin's disease (ZED) - A treatable entity.” In Blood, 92:88A-88A. W B SAUNDERS CO, 1998.
    Link to Item
  - “NCCN practice guidelines for the myelodysplastic syndromes. National Comprehensive Cancer Network.” In Oncology (Williston Park), 12:53–80, 1998.
    Link to Item
  - Aster, J., W. Pear, R. Hasserjian, H. Erba, F. Davi, B. Luo, M. Scott, D. Baltimore, and J. Sklar. “Functional analysis of the TAN-1 gene, a human homolog of Drosophila notch.” In Cold Spring Harb Symp Quant Biol, 59:125–36, 1994. https://doi.org/10.1101/sqb.1994.059.01.016.
    Full Text Link to Item
  - KEDES, L., A. MINTY, R. WADE, P. GUNNING, E. HARDEMAN, H. BLAU, P. BENTONVOSMAN, et al. “MULTILEVEL REGULATION OF GENE-EXPRESSION IN HUMAN MYOGENESIS - DISSOCIATION OF FACTORS RESPONSIBLE FOR MODULATION AND ACTIVATION AND EVIDENCE FOR NON-COORDINATE EXPRESSION.” In Journal of Cellular Biochemistry, 16–16. WILEY-LISS, 1986.
    Link to Item
Teaching & Mentoring
Advising & Mentoring
- I am available as an advisor or mentor for medical students, residents, fellows and junior faculty. Specifically, I am happy to provide advice regarding a career in academic medicine as a clinical investigator. I am interested in mentoring trainees and junior faculty in clinical investigation in leukemias, myelodysplastic syndromes and myeloproliferative neoplasms.
Scholarly, Clinical, & Service Activities
Service to the Profession
Academic & Administrative Activities
- Director, Leukemia Program
  Director, Phase I Development in Hematologic Malignancies
Clinical Activities
- Clinic hours:
  
  Monday, 12 p.m. to 5 p.m.
  Wednesday, 12 p.m. to 5 p.m.
  Thursday, 8 a.m. to 5 p.m.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Medical Licensure

Leadership & Clinical Positions at Duke

Academic Positions Outside Duke

Awards & Honors

Subject Headings

Global Scholarship

Research

Teaching

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Conference Papers

Advising & Mentoring

Service to the Profession

Academic & Administrative Activities

Clinical Activities